Prostate‐specific antigen patterns in US and European populations: comparison of six diverse cohorts

To determine whether there are differences in prostate‐specific antigen (PSA) levels at diagnosis or changes in PSA levels between US and European populations of men with and without prostate cancer (PCa).

[1]  Richard M Martin,et al.  Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes , 2016, Statistical methods in medical research.

[2]  L. Holmberg,et al.  Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study , 2015 .

[3]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[4]  L. Holmberg,et al.  Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. , 2015, European urology.

[5]  B. Trock,et al.  Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols , 2015, BJU international.

[6]  D. Dearnaley,et al.  Medium-term outcomes of active surveillance for localised prostate cancer. , 2013, European urology.

[7]  P. Scardino,et al.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study , 2013, BMJ : British Medical Journal.

[8]  M. Roobol,et al.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.

[9]  M. Soloway,et al.  Comprehensive analysis of post‐diagnostic prostate‐specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients , 2013, BJU international.

[10]  J. Hugosson,et al.  Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. , 2013, European urology.

[11]  M. Cooperberg,et al.  Active surveillance for prostate cancer: a systematic review of the literature. , 2012, European urology.

[12]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[13]  E. Holmberg,et al.  1094 Outcome following surveillance of men with screen-detected prostate cancer. Results from the Gothenburg randomised population-based prostate cancer screening trial , 2012 .

[14]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[15]  J. Cuzick,et al.  Evaluation of prediagnostic prostate‐specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively , 2011, International journal of cancer.

[16]  A. Billis.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience , 2011 .

[17]  David S. Yee,et al.  Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. , 2011, The Journal of urology.

[18]  Kirsten L. Greene,et al.  Outcomes of active surveillance for men with intermediate-risk prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Soloway,et al.  Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. , 2010, European urology.

[20]  Anna Kettermann,et al.  Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Hans Garmo,et al.  Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. , 2010, European urology.

[22]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C Metcalfe,et al.  Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study , 2009, British Journal of Cancer.

[24]  Andrew J Vickers,et al.  Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Taneja,et al.  Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. , 2009, Reviews in urology.

[26]  Alan Horwich,et al.  Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. , 2008, European urology.

[27]  L. Ferrucci,et al.  PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. , 2008, European urology.

[28]  P. Albertsen,et al.  Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. , 2008, The Journal of urology.

[29]  R. V. D. van den Bergh,et al.  Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. , 2008, European urology.

[30]  John T. Wei,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[31]  David Connolly,et al.  Methods of calculating prostate-specific antigen velocity. , 2007, European urology.

[32]  Joannie T. Yeh,et al.  Comparison of methods for calculating prostate specific antigen velocity. , 2006, The Journal of urology.

[33]  T. Daskivich,et al.  Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. , 2006, The Journal of urology.

[34]  Pankaj K Choudhary,et al.  Critical analysis of prostate‐specific antigen doubling time calculation methodology , 2006, Cancer.

[35]  J. Donovan,et al.  Establishing normal reference ranges for PSA change with age in a population‐based study: The Krimpen study , 2006, The Prostate.

[36]  P. Carroll,et al.  20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .

[37]  M. Barry.  Gleason score predicted mortality rate to 20 years for untreated early prostate cancer , 2005 .

[38]  Richard Kahn,et al.  Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association , 2004, Stroke.

[39]  R. Kahn,et al.  Preventing cancer, cardiovascular disease, and diabetes: a common agenda for theAmerican Cancer Society, the American Diabetes Association, and the American Heart Association. , 2004, CA: a cancer journal for clinicians.

[40]  Lurdes Y T Inoue,et al.  Combining longitudinal studies of PSA. , 2004, Biostatistics.

[41]  D. Siemens.  Radical prostatectomy or watchful waiting in early prostate cancer? , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[42]  Neil Fleshner,et al.  Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. , 2002, The Journal of urology.

[43]  J. Bosch,et al.  Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status , 2000, BJU international.